Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 6/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | REN | P00797 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TLR2 | O60603 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.31 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.31 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10074152 | 0.92 | DPP4 (0.36) | CTSDCTSSMEN1KMT2AREN | |
| SCHEMBL10074717 | 0.92 | REN (0.35) | CTSSRENTLR2 | |
| SCHEMBL6872783 | 0.92 | CTSD (0.34) | CTSDTLR2ENPP2 | |
| SCHEMBL10074455 | 0.88 | ENPP2 (0.39) | CTSSENPP2 | |
| SCHEMBL10074987 | 0.88 | ENPP2 (0.39) | CTSSENPP2 | |
| SCHEMBL10074154 | 0.87 | ENPP2 (0.38) | CTSDCTSSENPP2 | |
| SCHEMBL10074135 | 0.85 | CTSS (0.35) | CTSDCTSSCTSB | |
| SCHEMBL10078263 | 0.84 | CTSS (0.35) | CTSDCTSSRENCTSB | |
| SCHEMBL10078261 | 0.84 | PSMB11 (0.38) | CTSDCTSSRENCTSB | |
| SCHEMBL10078386 | 0.83 | CTSS (0.35) | CTSDCTSSRENCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2418196-A1 | Dual alanyl-aminopeptidase and dipeptidyl-peptidase IV inhibitors | IMTM GmbH (DE) | 2012-02-15 | — | — | EP | disclosed |
| US-20120028995-A1 | NOVEL COMPOUNDS FOR MEDICAL USE AS PEPTIDASE EFFECTORS | IMTM GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028995-A1 | NOVEL COMPOUNDS FOR MEDICAL USE AS PEPTIDASE EFFECTORS | SERPINB1, CMA1, CPA3 | CTSD 54/4885CTSS 43/4885MEN1 3747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.